Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy

@article{Vogl2006HepaticIC,
  title={Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy},
  author={Thomas J. Vogl and Wolfram O. Schwarz and Katrin Eichler and Kathrin Hochmuth and Renate M. Hammerstingl and Ursula Jacob and Albert Scheller and Stephan Zangos and Matthias Heller},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={2006},
  volume={132},
  pages={745-755}
}
To define the maximum tolerated dose (MTD) of hepatic intraarterial chemotherapy with gemcitabine, administered with and without starch microspheres, in patients with inoperable intrahepatic cholangiocarcinomas and liver metastases of pancreatic carcinomas. Gemcitabine was administered on days 1 and 8 with intervals of 2 weeks between the cycles. In group A the initial gemcitabine dose of 1,000 mg/m2 (without microspheres) was increased in 200-mg/m2 steps up to a maximum dose of 2,000 mg/m2. In… CONTINUE READING
23 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Intraarterial gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma

  • A Weissmann, H Ludwig
  • Proc Am Soc Clin Oncol
  • 1999
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…